Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

January 9, 2024

https://www.globenewswire.com/news-release/2024/01/09/2806211/0/en/Cogent-Biosciences-Announces-Planned-2024-Milestones-for-Bezuclastinib-and-Emerging-Portfolio-of-Selective-and-Potent-Targeted-Therapeutics.html

WALTHAM, Mass. and BOULDER, Colo., Jan. 09, 2024 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today highlighted the company’s key 2024 milestones ahead of its presentation at J.P. Morgan’s 42nd annual healthcare conference.

Read more at globenewswire.com

Related news for (COGT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.